United Therapeutics (UTHR) CEO Rothblatt Sells $5.1M of Stock

Martine Rothblatt, the Chairperson and CEO of United Therapeutics Corporation (NasdaqGS: UTHR), sold 9,500 shares valued at about $5.13 million on June 18, 2026. The shares were sold at an average price of $540.18 each, and this transaction was part of a planned selling strategy.

This sale follows a series of transactions by Rothblatt, including a buy of 9,500 shares on June 25, 2026, for approximately $1.29 million, and another buy on June 22, 2026, valued at about $1.32 million. On June 26, 2026, Rothblatt also sold 9,500 shares again, indicating a pattern of active trading in her holdings.

While no peer funds were reported making similar moves, it’s worth noting that Rothblatt's activity seems to align with her recent trading patterns. The stock has seen fluctuations, with the recent high reaching $609.35, and it closed at $544.40 on the day of the sale.

United Therapeutics focuses on developing and commercializing treatments for patients with chronic and life-threatening diseases. The company's innovative products include inhaled solutions and injections for pulmonary arterial hypertension, among others.

Analysts have a generally positive outlook on United Therapeutics. On October 8, 2026, RBC Capital maintained an 'Outperform' rating with a target price of $708. Morgan Stanley also held an 'Equal-Weight' rating with a target of $566. The consensus rating across 12 analysts is a 'buy', with a mean price target set at $664.33.

As United Therapeutics prepares for its next earnings report on October 28, 2026, investor interest may grow in light of recent insider trading activity. The recent sales by Rothblatt reflect holdings as of the reporting period and may not represent her current position. Investors will likely keep an eye on any further developments or filings from the company.